exposure limits, based on air sampling in the breathing zone, are set in most industrialised countries to help control personal exposure to airborne contaminants. In addition, biological exposure limits, based on blood or urinary levels of the contaminant, or one of its stable breakdown products, can also sometimes be used to assess uptake and thus control over-exposure. In either case, they are being used as presumed surrogates of risk.
The occupational environment has been most developed principally because exposure to hazardous contaminants has been most intense; it has usually provided the clearest evidence of ill health following exposure, and control of the workplace environment has generally been seen to be a fairly politically neutral activity. The principal argument is the cost of control versus risk of adverse health outcome, rather than infringement of civil liberties or other social issues. Such standard setting based on health effects is clearly most easily and acceptably performed where the contaminant has a defined threshold; that is, where a concentration below which it is generally accepted, on a reasonable toxicological data base, that no harm (acute or chronic) will occur even after repeated and continual exposure. This is fine for effects such as acute irritation or even chronic effects such as scarring diseases of the lungs or liver from repeated over-exposure. In these cases, we have a fairly good idea of where the thresholds lie and we usually have the means of controlling exposure to the causative agents below such threshold levels.
The problem is not so easy, however, for substances which have genotoxic properties, such as many carcinogens, where it is not possible to set a threshold unequivocally below which it can be 'guaranteed' that no risk exists, given a very large population.
Genotoxic carcinogens are thought to operate by causing initial fundamental and inheritable changes to nuclear DNA in the target cells.
In such circumstances, the regulatory approach to standard setting varies. Some bodies decline to make what is essentially an 'acceptable' or 'tolerable' risk assessment, but instead, publish lowest technically achievable levels as guide-lines for good practice with perhaps an upper limit to indicate what may be considered to be unacceptable. In this, and in other areas of indoor or outdoor exposure to genotoxic carcinogens, the regulators or standard-setting bodies may attempt to extrapolate downwards from the data available on health outcome and exposure levels to presumed risks at much lower levels for a different population who may be exposed. 58 Here, the extrapolation downwards is often based upon uncertain biological mechanisms, mathematical modelling, and estimates of dose, so the assumptions become piled on top of each other. In fairness, however, it should be stated that the options available to make judgements in risk assessment are limited. Often the starting point for such risk assessment is the use of contemporary breathing zone exposures, which must then be compared with health effects (cancers in this case) from exposures as long as 30 or 40 years previously. From such data, some kind of dose-response curve is constructed and downward extrapolation to low levels, based on a number of biological and mathematical assumptions, can be used to produce risk estimates. Here, the exposure concentration becomes a surrogate for risk. The real problem is that in spite of the often elegant mathematical modelling, the answers can only be as good as the biological assumptions made regarding the probable cancer-causing mechanisms, the quality and reliability of the exposure estimates and the accuracy of the health data. As an example, there is at present a great debate in progress regarding the setting of both occupational and environmental standards for benzene exposure. This ubiquitous aromatic hydrocarbon has been shown to be a human carcinogen, causing a certain kind of leukaemia in a number of studies of occupationally-exposed workers. In addition, although it is certainly not comprehensively genotoxic in a wide range of short-term predictive tests for mutagenicity/carcinogenicity, it has produced damage to chromosomes in a number of studies and thus it is generally considered prudent to assume it to be a genotoxic carcinogen.
There have been a number of mathematical models used for lowlevel risk extrapolation for benzene to produce 'acceptable' levels of risk, and in the occupational setting (based on an 8 h per day/5 days per week exposure) they give exposure levels ranging from 0.1 to over 10 ppm for the same level of risk for leukaemia induction. This is hardly surprising if one examines the data within the epidemiological studies on which the various models rest.
Probably the best study of those available for evaluation is that of Rinsky et al. [Benzene and leukaemia -An epidemiologic risk assessment. N Engl J Med 1987;316: 1044-1050] yet this consists of a series of only 9 cases of leukaemia and there is quite a bit of uncertainty regarding the levels of benzene to which the nine cases have been exposed. Again it should not surprise anyone that there is some scepticism regarding the use of mathematical modelling for extrapolation of risk from high to low dose. It is also worth noting that benzene is considered one of the 'better understood and documented' carcinogens for the purposes of risk extrapolation. To pile on the problems a little more, it is also noteworthy that in spite of a large amount of competent research on benzene carcinogenicity, we still have no clear understanding of how it causes leukaemia. On a more general note, although there is quite a lot of use made of mathematical modelling for the purposes of low-dose risk assessment of carcinogens by bodies such as the EPA in the US, in Europe it is less commonly used.
Thus, because of some of the difficulties exemplified above, for preventive purposes it is becoming recognised that it may not be the best long-term strategy for us to rely so heavily on such conventional epide-miological methods (morbidity or mortality against exposure) to either tell us much about causality, or give us clear estimates of risk. Often the long latency period between first exposure to carcinogen and diagnosis of cancer precludes reliable estimates of exposure. Also, epidemiology tells us nothing about mechanisms or host factors (individual responses to carcinogens) in such a complex multistage process as chemically-induced cancer. However, before we berate the standard-setters and regulators for using inappropriate models, incomplete data and sophistry for the production of barely defensible standards, we need to ask whether the scientific community has anything better, or even in addition to offer them. After all, the regulatory authorities have the responsibility to protect, and, in the face of uncertainty, should be expected to adopt 'fail to safety' options and thus choose the prudent path.
During the last decade, a range of new techniques have been developed at an increasingly rapid pace. These may help us in a number of ways in risk estimation. They rely much more on various means of assessing the effect of internal dose rather than using exposure in ambient air. Many of these techniques involve some form of general or more specific DNA damage in the cells of people who have been or are being exposed to substances or atmospheres where there is known to be an increased risk of cancer. Usually they have been applied in the occupational setting, but such techniques have also been applied to study the effects in patients receiving cytotoxic drugs Many of the biomonitoring techniques rely on the measurement of the interaction between the contaminant and either nuclear DNA itself or, some protein or macromolecule in cells. At first sight, such an approach appears to be conceptually satisfying, as it is compatible with most theories of carcinogenesis which include some form of damage to DNA as a prerequisite for cancer induction. It would thus seem to appear that we are measuring the 'real thing'a surrogate to be trusted.
However, before we all rush off to use these techniques as our new 'risk estimates' for carcinogens, there is a need to inject some caution into our thinking, both in the use of these techniques and the interpretation of any ensuing results. Many of us will recall the confident claims made in the early days of the development of short-term predictive screening tests for carcinogens. Then, some of the advocates of tests such as the bacterial point mutation test (Ames Test) would have led us to believe that the chemical world could simply be divided into non-carcinogens and carcinogens, or very nearly so, and that these fairly simple tests could distin-guish between them. Nowadays, more sober thoughts prevail and we realise that life, and certainly chemicals, do not always obey simple rules. Thus, short-term predictive tests, thoughtfully applied, can be extremely helpful in assisting our overall evaluation of the genetic toxicology, and perhaps the potential carcinogenicity of substances to which people are exposed.
It is somewhat comforting that the toxicological scientific community has in general moved on, and exaggerated or wild claims are not being made regarding the use and predictive powers of these relatively new test systems. Notwithstanding the imprecision of conventional epidemiology and the ensuing scepticism surrounding the use of mathematical modelling for low-dose extrapolation, the use of biomonitoring to help assess risk for carcinogenic atmospheres can be justified on fairly logical grounds. Cancers caused by occupational and environmental substances have latent periods often in the range of 10-40 years, depending on the cancer type. Thus, the earlier one picks up a potential carcinogenic problem, without waiting for evidence from human cancers, the better. In addition, although cancer is a complex multistage process, it is generally accepted that nuclear DNA damage will occur at an early stage in the process. Finally, because many carcinogens are genotoxic, it is often possible to measure damage or alteration to the DNA either directly or indirectly. Thus one is led inexorably to the conclusion that if there is some sequential correlation between a carcinogenic substance causing DNA damage at an early stage and cancer, the possibility must exist for such damage to be measured and exploited as a biomarker in a number of ways. Amongst these ways will be its use as a biomarker or surrogate of risk. This latter approach is the thinking that is potentially most open to over-interpretation and over-optimistic claims. It is here that the developers and users of such techniques must be clearest about what the results of their studies mean and more particularly about what they do not mean. Overall, the possible use of such biomonitoring can be classified as follows:
( 1 ) They can be used as a means of assessing 'internal dose' of the substance.
(2) They can be used to examine host factors and help explain individual variation in response to carcinogen exposure.
(3) They can continue to be of great use to examine specific kinds of DNA damage which will aid in the understanding of the carcinogenic process.
(4) If the quantitative aspects of .,Iè the techniques can be developed so r we gain a better understanding of the relevance of these lesions in the carcinogenic process, it may lead to their use as a surrogate of risk and thus as a possible useful tool for control or regulatory purposes. At present, all of the first three areas are under much active research.
In the case of the fourth, there is the hope that it will develop along sound lines, but also present is the potential danger that it will evolve prematurely without a clear understanding of its limitations.
The range of these techniques used by molecular biologists working in carcinogenesis or molecular epidemiology is quite wide. Many are based on measuring some biomarker that is formed by the reaction between the toxic substance and a relevant macromolecule, usually DNA or a protein, to form an adduct.
Other techniques are available that look at more general DNA or chromosome damage and changes that may be related to carcinogen exposure. Most of the techniques can be applied to a range of biological tissues or fluids for experimental purposes, but for practical sampling techniques, blood or urine are those most popular and useful. The formation and identification of DNA adducts from human blood lymphocytes or the formation of haemoglobin adducts appear to be developing most rapidly as possible field techniques. The former, in particular, would appear to have the most relevance to carcinogenesis: this of course assumes that the DNA adduct that is formed and measured is one that has some role in the carcinogenic process. Although the application is fairly new, the science behind the use of DNA adducts in research goes back quite a long way in cancer investigation. In this area it has been used for research into mechanisms, but was never considered as a means of biomonitoring for epidemiological purposes. The biological basis of the technique is that many carcinogens are highly reactive and known to form reactive (electrophilic) metabolites that can covalently bind to DNA. This may in itself be a critical early event in the carcinogenic process. In human cells, such DNA damage is often repaired and thus, the bit of DNA that is attached to the covalently bound bit of carcinogenic metabolite is removed. It is in the measurement of these DNA adducts that most recent progress has been made by the use of very sensitive techniques for characterising and measuring these adducts. Such techniques include enzyme-linked immunosorbent assay (ELISA) and the very sensitive 32P-post-labelling assay. This latter technique exploits the changes in chromatographic mobility of DNA adducts from normal DNA bases. This simply means that the DNA adducts can be separated from the other bits of normal DNA and subsequently identified when the nucleus is broken up. The technique has been shown to work well for a fairly broad range of chemicals, and for smaller as well as large adducts. One drawback is a lack of specificity, i.e. the exact chemical identity of the adduct is not known. However, the technique can be combined with immunoassay, and if an ensuing antibody can be formed, then specificity will be added.
The technique of DNA adduct monitoring has been applied to a number of groups of workers who have been exposed to polycyclic aromatic hydrocarbons, and who are known from epidemiological investigations to experience an increased risk of developing lung cancer. These groups include iron foundry workers and coke-oven workers. The results show that although there is an overall difference in adduct formation between exposed groups and unexposed controls, there is a wide range of individual results with overlap between exposed and unexposed. Thus, although, such techniques may eventually be refined or better understood so that they may well make a better surrogate for risk than simply measuring air levels of contaminants per se, we should avoid the temptation to rush ahead with unsupported extrapolations. Instead, as is happening, we should allow the field to develop thoughtfully. Clearly, the techniques could be extremely useful if we could establish the toxicological significance of the adducts formed and measured: not all adducts may have relevance to carcinogenesis, although they may make excellent markers of exposure. We need to have more specific chemical identification of the adducts themselves to avoid accusations of non-specificity. If the technique is applied to routinely available biological samples, such as blood, then we next need to know if the blood lymphocytes used for assessing DNA adduct formation are truly a good surrogate for bronchial epithelial cells that are the cell types from which human lung tumours arise. This is particularly important if we are considering an environment that is known to be associated with an increased risk of lung cancer. These are but a few questions that have to be addressed as the field of molecular epidemiology, molecular dosimetry, molecular biomonitoring, or whatever it ends up being called, develops. I would have thought that we have learned enough from past mistakes in the techniques of risk assessment relating to hazardous substances not to push these and other fundamental questions aside in our haste to produce rapid answers for decision makers. Rather we should share with them the scientific uncertainties that exist when inferring risk from the use of such helpful surrogates. . ; j:.... , '
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